Chemotherapy for Gram-positive nosocomial sepsis

Journal of Chemotherapy

Volumn 11, Issue 6, 1999, Pages 446-452

  Wood, M J ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Glycopeptides; Gram positive infections; Resistance; Streptogramins

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; EVERNINOMICIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; ORITAVANCIN; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MIXTURE; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; SEPSIS; STAPHYLOCOCCUS AUREUS;

EID: 0033387246     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.6.446     Document Type: Conference Paper

References (34)

1. 1 Cockerill FR, Hughes JG, Vetter EA, et al. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: trends in microorganisms isolated and the value of anaerobic culture of blood. Clin Infect Dis 1997; 24: 403-418.
2. 2 Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24: 584-602.
3. 3 Mizushima Y, Kawasaki A, Hirata H et al. An analysis of bacteraemia in a university hospital in Japan over a 10-year period. J Hosp Infect 1994; 28: 285-298.
4. 4 Centers for Disease Control. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. Am J Infect Contr 1996; 24: 380-388.
5. 5 Bouza E, Pérez-Molina J, Muñoz P. Report of ESGNI-001 and ESGNI-002 studies. Bloodstream infections in Europe. Clin Microbiol Infect 1999; 5: 2S1-2S12.
6. 6 Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996; 15: 281-285.
7. 7 Fagon JY, Chastre J, Domart Y et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Resp Dis 1984; 139: 877-884.
8. 8 Bartlett JG, O'Keefe P, Tally FP, Louis TJ, Gorbach SL. Bacteriology of hospital-acquired pneumonia. Arch Intern Med 1986; 146: 868-871.
9. 9 Raad I. Intravascular catheter-related infections. Lancet 1998; 351: 893-898.
10. 10 Moellering RC, Jr. Problems with antimicrobial resistance in Gram-positive cocci. Clin Infect Dis 1998; 26: 1177-1178.
11. 11 Centers for Disease Control. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. MMWR 1997; 46: 813-815.
12. 12 Voss A, Milatovic D, Wallrauchschwarz C, Rosdahl VT, Braveny I. Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994; 13: 50-55.
13. 13 Johnson AP, James D. Continuing increase in invasive methicillin-resistant Staphylococcus aureus infections. Lancet 1997; 350: 1710-1710.
14. 14 Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR 1993; 42: 597-599.
15. 15 Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
16. 16 Centers for Disease Control. Sraphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 1997; 46: 765-766.
17. 17 Nichols RL. Surgical infections: prevention and treatment - 1965-1995. Am J Surg 1996; 172: 68-74.
18. 18 Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
19. 19 Speller DCE, Johnson AP, James D et al. Resistance to methicillin and other antibiotics in Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997; 350: 323-325.
20. 20 Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1995; 23: 767-772
21. 21 Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns. Drugs 1997; 54 (suppl 6): 11-20.
22. 22 Catchpole C, Wise R, Fraise A. MRSA bacteraemia. J Hosp Infect 1997; 35: 159-161.
23. 23 Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-1133
24. 24 Mouthon L, Mainardi J-L. Vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus: the gram-positive challenges. Curr Opin Infect Dis 1996; 9: 256-260.
25. 25 Cookson B, Phillips I. Epidemic methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 21(Suppl C): 57-65.
26. 26 The Hospital Infection Control Practice Advisory Committee. Recommendations for preventing the spread of vancomycin resistance: recommendations from the Hospital Infection Control Practices Advisory Committee (HICPAC). Am J Infect Contr 1995; 23: 87-94.
27. 27 Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
28. 28 Grüneberg RN. Anti-gram-positive agents: what we have and what we would like. Drugs 1997; 54(Suppl 6): 29-38.
29. 29 Batts DH. Linezolid clinical development program: end of Phase II results. Abstracts of 2nd European Congress of Chemotherapy, Hamburg, Germany, 10-13 May 1998.
30. 30 Nichols R, US Synercid SSSI Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus standard therapy (ofloxacillin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). Programme and Abstracts of the 20th International Congress of Chemotherapy, June 29-July 3 1997, Sydney, Australia . p43 (Abstract)
31. 31 Beal J, Global Synercid SSSI Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). Programme and Abstracts of the 20th International Congress of Chemotherapy, June 29-July 3 1997, Sydney, Australia p 44 (Abstract)
32. 32 Fagon JY, Global Synercid NP Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (RP 59500, Synercid®) plus aztreonam versus vancomycin plus aztreonam in the treatment of Gram-positive nosocomial pneumonia (NP). Programme and Abstracts of the 20th International Congress of Chemotherapy, June 29-July 3 1997, Sydney, Australia p 44. (Abstract)
33. 33 Raad I, The Global Synercid CRGPB Study Group. Dose-ranging randomized, multicenter, open phase II study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) versus vancomycin in the treatment of catheter-related, Gram-positive bacteremia (CRGPB). Programme and Abstracts of the 20th International Congress of Chemotherapy, June 29-July 3 1997, Sydney, Australia p 45 (Abstract)
34. 34 Moellering RC, Linden PK, Synercid Emergency-Use Study Group. Efficacy and safety of quinupristin/dalfopristin (RP 59500, Synercid®) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections. Programme and Abstracts of the 20th International Congress of Chemotherapy, June 29-July 3 1997, Sydney, Australia p 4. (Abstract)